Live Breaking News & Updates on Rituxan

Stay updated with breaking news from Rituxan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Progressive Treatment Strategies for DLBCL Directed by NCCN Guidelines

A medical expert examines first6, second-, and third-line systemic therapies for DLBCL in accordance with NCCN Guidelines. ....

United States , Catherine Thieblemont , Cleo Gordon , New England Journal , Clinical Oncology , B Cell Lymphoma , Nccn Guidelines , Chop Chemotherapy , Phoenix Clinical Trial , Transform Study ,

Fixed-Duration Data Foreshadow Earlier Use of Loncastuximab Tesirine in Relapsed/Refractory DLBCL

Loncastuximab tesirine-lpyl plus rituximab demonstrated promising antitumor activity and consistent safety signals in patients with relapsed/refractory diffuse large B-cell lymphoma. ....

United States , Michal Kwiatek , Mohamed Zaki , Society Of Hematologic Oncology , Centrum Medyczne Pratia Poznan , Ann Arbor , Hematologic Oncology , Society Of Hematologic Oncology Annual Meeting Soho , Non Hodgkin Lymphoma , Relapsed Refractory Diffuse Largeb Cell Lymphoma , Phase 3 Lotis 5 Trial ,

Dr Phillips on the Evaluation of Frontline Treatment With Acalabrutinib Plus BR in MCL

Tycel Phillips, MD, MPH, discusses the ongoing phase 3 ECHO trial of acalabrutinib plus bendamustine and rituximab in the front line for patients with mantle cell lymphoma. ....

Tycel Phillips , Department Of Hematology Hematopoietic Cell Transplantation , Division Of Lymphoma , Hematopoietic Cell Transplantation , City Of Hope , Onclive Tv , Mantle Cell Lymphoma ,

Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated Follicular Lymphoma, MZL

The addition of ibrutinib to bendamustine plus rituximab or R-CHOP did not lead to a statistically significant improvement in progression-free survival vs either chemoimmunotherapy regimen alone in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma. ....

United States , Daiichi Sankyo , Arturo Pavlovsky , Lorettaj Nastoupil , Department Of Lymphoma Myeloma , University Of Texas Md Anderson Cancer Center , Drug Development , Division Of Cancer Medicine , International Conference On Malignant Lymphoma , Annual International Conference , Lymphoma Outcomes Database , New Drug Development , Cancer Medicine , Cancer Center , Caribou Biosciences , International Conference , Malignant Lymphoma , Non Hodgkin Lymphoma , Hematologic Oncology , Relapsed Refractory Follicular Lymphoma Or Marginal Zone , Phase 3 Selene Trial , 17th Annual International Conference On Malignant Lymphoma ,

Dr Phillips on the Investigation of Acalabrutinib/Benendamustine/Rituximab in MCL

Tycel Phillips, MD, MPH, discusses the safety and efficacy of acalabrutinib plus bendamustine and rituximab from a phase 1 trial in patients with treatment-naive and relapsed/refractory mantle cell lymphoma.
....

Tycel Phillips , Division Of Lymphoma , Department Of Hematology Hematopoietic Cell Transplantation , Hematopoietic Cell Transplantation , City Of Hope , Onclive Tv , Mantle Cell Lymphoma ,